J 2015

The Role of Hyaluronan in Asherman’s Syndrome Therapy

KRAJČOVIČOVÁ, Renáta, Robert HUDEČEK, Pavel VENTRUBA a Katarína SURGENTOVÁ

Základní údaje

Originální název

The Role of Hyaluronan in Asherman’s Syndrome Therapy

Autoři

KRAJČOVIČOVÁ, Renáta (703 Slovensko, garant), Robert HUDEČEK (203 Česká republika, domácí), Pavel VENTRUBA (203 Česká republika, domácí) a Katarína SURGENTOVÁ (203 Česká republika)

Vydání

Journal of gynecologic surgery, Larchmont, Mary Ann Liebert Inc. 2015, 1042-4067

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.153 v roce 1999

Kód RIV

RIV/00216224:14110/15:00084696

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000218245500002

Klíčová slova anglicky

Asherman´s syndrome; menstrual cycle; hormonal therapy; hyaluronan

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 16. 12. 2015 17:11, Soňa Böhmová

Anotace

V originále

Prospective clinical evaluation comparing the therapy of Asherman’s syndrome in patients treated using hysteroscopic (HSK) adhesiolysis with insertion of 100% hyaluronic acid (HA) to a patient cohort with an inserted intrauterine device (IUD) and a control cohort. Design: Primary outcome—treatment for menstrual cycle problems. Secondary outcome—attainment of pregnancy after spontaneous conception within 1 year after the ending of hormonal therapy. Materials and Methods: Sixty patients treated from 1997 to 2014 for Asherman’s syndrome (in Stage II and III). Cohort A: Insertion of 100% HA (20 patients). Cohort B: Insertion of an IUD (18 patients). Cohort C: Without insertion of antiadhesion agent (22 patients). Primary and secondary goals were evaluated for all patients after a 3-month hormonal therapy. Results: The normal menstrual cycle was restored in 12 out of 20 patients in cohort A (60.0%), in 10 out of 18 patients in cohort B (55.5%), and 8 out of 22 patients in control cohort C (36.3%). A spontaneous pregnancy within 1 year after the end of the treatment was achieved by 14 out of 18 patients (77.7%) in cohort A, by 6 out of 10 patients (60.0%) in cohort B, and by 6 out of 14 patients (42.8%) in cohort C. Ten patients (55.5%) gave birth in cohort A, 4 patients (40.0%) in cohort B, and 4 patients (28.5%) in cohort C. Given the small number of the included patients, there was no statistically significant difference identified in any of the followed cohorts through the completed statistical analysis. Conclusion: Intrauterine insertion of hyaluronan after the completed HSK adhesiolysis enabled the recovery of the normal menstrual cycle for 60.0% of the patients and improved the implantation rate (77.7%) and take home baby rate (55.5%), compared to the group of patients with insertion IUD and with the control group. ( J GYNECOL SURG 31:250)